Skip to main content

Fiscal Wizard · Single-issue tearsheet

EVO / Jun 21, 2026 Run #7417

EVO

Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Composite verdict

F 13.8 / 100
Bearish setup · Trend Following 12 drivers · 4 gates blocking
  • Chaikin Money Flow
  • Aroon Oscillator
  • Keltner Channels
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 61st of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 0Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -45%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

27.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Inventory Turnover 100
Margin of Safety 0
EV/Sales 75
Free Cash Flow Yield 0
P/B 75
EV/EBITDA 25

Technicals Bearish

0.0 / 100

Bearish setup leads (Chaikin Money Flow, Aroon Oscillator, Keltner Channels); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 11
Rate of Change 11
Keltner Channels 12

Risk Gates

4 blocking 3 caution

4 guards active, 21 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for EVO.